Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients.

Andrea J HaddadRay Y HachemMohamed MoussaYing JiangHiba R Dagher Patrick S ChaftariAnne-Marie ChaftariIssam I Raad

Published in: Cancers (2024)

In the treatment of mild-to-moderate COVID-19 in cancer patients, Molnupiravir was comparable to Nirmatrelvir/Ritonavir in preventing progression to severe disease/death and rebound events, and it had a superior safety profile.

Keyphrases

coronavirus disease
sars cov
early onset
replacement therapy
respiratory syndrome coronavirus